NiKang Therapeutics
Nikang Therapeutics, established in 2017, is a clinical-stage biotech company dedicated to developing innovative small molecule drugs for cancer treatment. Their mission is to develop precision medicine to address highly unmet medical needs, such as cancer, through disease biology insights and structure-based drug design. They focus on targets like HIF2α, CDK2, and KRAS, and have advanced three small molecule drugs into first-in-human clinical testing for difficult-to-drug targets.
Industries
Nr. of Employees
medium (51-250)
NiKang Therapeutics
Patents
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-12171741-B2
View DetailsTetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-11753366-B2
View Details
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-12171741-B2
View DetailsTetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
US-11753366-B2
View DetailsProducts
Clinical-stage HIF2α small-molecule inhibitor
A small-molecule inhibitor targeting HIF2α advanced into early clinical studies for clear-cell renal cell carcinoma and other solid tumors.
Clinical-stage selective CDK2 inhibitor
An orally bioavailable, selective small-molecule inhibitor of CDK2 advanced into early-phase clinical testing; reported to reduce cyclin E expression in preclinical/early clinical studies.
Clinical-stage CDK2 degrader (targeted protein degrader)
An orally bioavailable targeted protein degrader program directed at CDK2 that has progressed into early clinical evaluation, including cohort dosing milestones.
Discovered SHP2 small-molecule program (externally partnered)
Discovery and early development of a SHP2-targeting small molecule that has been advanced into clinical evaluation through an external partner's trial.
NKT2152
NKT2152 is a potent, selective, and orally available small molecule HIF2α inhibitor designed to disrupt the HIF2α/HIF1β transcription factor complex.
NKT5097
NKT5097 is a first-in-class, highly potent and selective, orally bioavailable CDK2/4 dual degrader designed to achieve simultaneous inhibition of the CDK2 and CDK4 pathways.
Clinical-stage HIF2α small-molecule inhibitor
A small-molecule inhibitor targeting HIF2α advanced into early clinical studies for clear-cell renal cell carcinoma and other solid tumors.
Clinical-stage selective CDK2 inhibitor
An orally bioavailable, selective small-molecule inhibitor of CDK2 advanced into early-phase clinical testing; reported to reduce cyclin E expression in preclinical/early clinical studies.
Clinical-stage CDK2 degrader (targeted protein degrader)
An orally bioavailable targeted protein degrader program directed at CDK2 that has progressed into early clinical evaluation, including cohort dosing milestones.
Discovered SHP2 small-molecule program (externally partnered)
Discovery and early development of a SHP2-targeting small molecule that has been advanced into clinical evaluation through an external partner's trial.
NKT2152
NKT2152 is a potent, selective, and orally available small molecule HIF2α inhibitor designed to disrupt the HIF2α/HIF1β transcription factor complex.
NKT5097
NKT5097 is a first-in-class, highly potent and selective, orally bioavailable CDK2/4 dual degrader designed to achieve simultaneous inhibition of the CDK2 and CDK4 pathways.
Services
Partnering with external pharmaceutical organizations to run combination studies and provide clinical supply under collaboration agreements.
Out-licensing and regional licensing arrangements to enable development and commercialization in specific territories.
Partnering with external pharmaceutical organizations to run combination studies and provide clinical supply under collaboration agreements.
Out-licensing and regional licensing arrangements to enable development and commercialization in specific territories.
Expertise Areas
- Structure-based small-molecule drug discovery
- Oncology therapeutic development (early phase)
- Targeted protein degradation (PROTACs)
- Translational biomarker discovery and patient stratification
Key Technologies
- Structure-based drug design
- Proteolysis-targeting chimeras (PROTAC) development
- Small-molecule kinase and transcriptional regulator inhibition
- Cellular assay development